Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Sara Torres-EsquiusDepartment of Hematology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-7540-7284
Guillermo Ramil-LópezDepartment of Hematology, Hospital de Santa Creu i Sant Pau, Institut de Recerca Sant Pau, Barcelona, Spain.ORCID 0009-0005-0287-6967
Maria Gabarrós-SubiràDepartment of Hematology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-2979-1681
Marta PratcoronaDepartment of Hematology, Hospital de Santa Creu i Sant Pau, Institut de Recerca Sant Pau, Barcelona, Spain.ORCID 0000-0001-6375-596X
David ValcarcelDepartment of Hematology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-8747-078X
Francesc BoschDepartment of Hematology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Andrés JerezDepartment of Hematology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-2079-6638
Maria Julia MontoroDepartment of Hematology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-9532-7417
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition. · full record | OpenQuestion